Ensysce Biosciences (ENSCW) Preferred Stock Liabilities (2019 - 2020)
Ensysce Biosciences (ENSCW) reported Preferred Stock Liabilities of $52935.0 for Q4 2020, down 99.97% year-over-year from $181.2 million in Q1 2020, and down 80.47% quarter-over-quarter from $270999.0 in Q3 2020.
Ensysce Biosciences (ENSCW) Preferred Stock Liabilities (2019 - 2020) Analysis & Trends
Ensysce Biosciences (ENSCW) has 2 years of Preferred Stock Liabilities data on file, last reported at $52935.0 in Q4 2020.
- Preferred Stock Liabilities for Q4 2020 came in at $52935.0, down 99.97% year-over-year; the trailing twelve-month figure through Dec 2020 was $52935.0 (down 99.97% YoY), and the FY2020 annual result was $52935.0, down 99.97% from the prior year.
- Preferred Stock Liabilities declined to $52935.0 in Q4 2020 per ENSCW's latest filing, from $270999.0 in the prior quarter.
- Over five years, Preferred Stock Liabilities peaked at $181.2 million in Q4 2019 and troughed at $52179.0 in Q2 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Ensysce Biosciences | - | - | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2020 | 52,935.00 |
| Sep 30, 2020 | 270,999.00 |
| Jun 30, 2020 | 52,179.00 |
| Mar 31, 2020 | 4.54 Mn |
| Dec 31, 2019 | 181.17 Mn |